Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 5/20 | 0.41 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.36 |
| ▸ | IP6K1 | Q92551 | 2/20 | 0.34 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.33 |
| ▸ | MPO | P05164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29818537 | 1.00 | ACACB (0.41) | ACACBTBK1IP6K1MALT1CHRM4 | |
| SCHEMBL31378759 | 0.82 | IRAK4 (0.33) | ACACBKDM4EUSP2ALDH1A1 | |
| SCHEMBL26600712 | 0.81 | ACACB (0.41) | ACACBTBK1IP6K1MALT1CHRM4 | |
| SCHEMBL13514630 | 0.77 | KDM4E (0.40) | KDM4EUSP2ALDH1A1 | |
| SCHEMBL18839637 | 0.76 | KDM4E (0.49) | KDM4EUSP2ALDH1A1 | |
| SCHEMBL31046671 | 0.76 | KDM4E (0.49) | KDM4EUSP2ALDH1A1 | |
| SCHEMBL20319433 | 0.75 | ACACB (0.44) | ACACBTBK1IP6K1MALT1 | |
| SCHEMBL20265583 | 0.75 | GAA (0.46) | ACACBALDH1A1 | |
| SCHEMBL20265434 | 0.75 | MALT1 (0.39) | ACACBIP6K1MALT1 | |
| SCHEMBL23343502 | 0.74 | HTT (0.41) | ACACBIP6K1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3558969-B1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-18 | — | — | EP | disclosed |
| US-12077521-B2 | Pyrazole derivatives as MALT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-03 | — | — | US | disclosed |
| US-20240148732-A1 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS | SCHRÖDINGER, INC. | 2024-05-09 | — | — | US | disclosed |
| EP-4284804-A1 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS | Schrödinger, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| WO-2022164789-A9 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS | SCHRÖDINGER, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2022164789-A9 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS | SCHRÖDINGER, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| US-20220315557-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN BIOTECH, INC. | 2022-10-06 | — | — | US | disclosed |
| WO-2022164789-A1 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISODERS | SCHRÖDINGER, INC. (US) | 2022-08-04 | — | — | WO | disclosed |
| US-10954214-B2 | Pyrazole derivatives as MALT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-03-23 | — | — | US | disclosed |
| US-10954214-B2 | Pyrazole derivatives as MALT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-03-23 | — | — | US | disclosed |
| EP-3558969-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | Janssen Pharmaceutica NV (BE) | 2019-10-30 | — | — | EP | disclosed |
| WO-2018119036-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN BIOTECH, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018119036-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN BIOTECH, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| US-20180170909-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN-CILAG (FR) | 2018-06-21 | — | — | US | disclosed |
| US-20180170909-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN-CILAG (FR) | 2018-06-21 | — | — | US | disclosed |
| US-20180170909-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN-CILAG (FR) | 2018-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148732-A1 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS | MALT1, LITAF, IL2 | ACACB 541/4885TBK1 1841/4885IP6K1 1921/4885 |
| US-20220315557-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | MALT1, PPP3R1, SQSTM1 | ACACB 3783/4885TBK1 1833/4885IP6K1 827/4885 |
| US-10954214-B2 | Pyrazole derivatives as MALT1 inhibitors | MALT1, PPP3R1, SQSTM1 | ACACB 3783/4885TBK1 1833/4885IP6K1 827/4885 |
| US-12077521-B2 | Pyrazole derivatives as MALT1 inhibitors | MALT1, PPP3R1, SQSTM1 | ACACB 3783/4885TBK1 1833/4885IP6K1 827/4885 |
| US-20180170909-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | MALT1, PPP3R1, SQSTM1 | ACACB 3783/4885TBK1 1833/4885IP6K1 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.